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Abstract 
Background: To study  the effectiveness of 
Metformin in attaining pregnancy along with 
ovulation induction medicines in infertile women 
with polycystic ovary syndrome (PCOS) and  to 
determine beneficial effect of Metformin when 
taken during pregnancy. 
Methods: Metformin was started at an oral dose of 
500mg/day and maintained at 1500mg/ day for 3 
months in Group A(n=170) and 6 months in Group 
B(n=145). Then they were given ovulation induction 
medicines along with Metformin. Patients conceived 
were advised to take Metformin 750 mg/day in 
divided doses during the pregnancy. They were 
subdivided into Group I (those who continued 
Metformin during pregnancy) and Group II (those 
who did not continue Metformin during pregnancy.  
The parameters representing outcome of pregnancy 
such as live births, single births, multiple births, 
abortions, stillbirths, postnatal deaths, threatened 
abortions, pre term and post term delivery were 
observed. 
Results: Younger patients responded to the 
treatment in terms of conception which was not 
observed in the case of older infertile patients. 
Overall conceptions after three months treatment 
with Metformin  were highly significantly low 
(p=0.0001) compared to those who were given 
Metformin for six months.  Combination of 
Clomiphene citrate with Metformin and 
combination of Human Menopausal Gonadotrophin 
with Metformin resulted in 36.36% conceptions  in 
Group A and 64.18 % in Group B. In patients who 
continued Metformin during pregnancy single live 
births were more in group I of Group A and Group B 
while still births were more in group II of Group A 
(p=0.011) and B (p=0.005). In patients who did not 
continue Metformin during pregnancy complications 
like threatened abortion and abortion (p=0.006) were 
found in Group A and (p=0.002) in Group B. Preterm 
delivery (p=0.048) was seen in Group A and 
(p=0.085) in Group B. 
Conclusion: Conceptions after six months 
treatment with Metformin were significant as 
compared to those given Metformin for three 
months. Metformin taken during the pregnancy 
duration improved the outcome of pregnancy. 
Key Words:  Metformin, Ovulation induction 
medicines, Pregnancy, Outcome of Pregnancy 
 
Introduction 
          Polycystic ovary syndrome (PCOS) is the most 
common endocrine disorder among women of fertile 
age. It is the most common endocrinopathy in women 
and the most common cause of anovulatory infertility. 
1, 2 In addition to poor conception rates, pregnancy loss 
rates are high (30-50%) during the first trimester. 3 
Some studies have also described an increased 
miscarriage rate in PCOS, the mechanism of which is 
poorly understood. It has been suggested that high 
follicular phase concentrations of LH have a 
deleterious effect on rates of conception and 
miscarriage.4, 5 Metformin probably improves 
ovulation in women with PCOS by reducing 
gluconeogenesis, improving insulin sensitivity, and 
reducing ovarian androgen production .6 The 
pregnancy rates for metformin plus clomiphene were 
significantly higher than for clomiphene alone.7 
Without metformin, spontaneous abortion(SAB) is 
common in women with PCOS, occurring in 42% of 
pregnancies , 39% , 44%, and 73%.3,8,9,10 It was 
postulated that Metformin’s reduction in Plasminogen 
activator inhibitor (PAI-Fx)  contributed to the 
reduction in SAB .3,8 Use of Metformin during 
pregnancy reduced the rate of miscarriage. No 
congenital anomaly, intrauterine death or still birth 
was reported.11The present study was designed to 
investigate the effects of Metformin along with 
ovulation induction medicines in achieving pregnancy 
and effects of Metformin in pregnant females. 
 
Patients and Methods  
     The sample size was calculated by using the 
statistical formula  keeping power of study to 80% and  
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level of significance equal to 5%.12 The sample size 
estimated was 147 in each group. The study 
population included women treated for infertility seen 
during a period of one and half year at the Pakistan 
Institute of Medical Sciences Noor specialized clinic 
Islamabad. Patients with disturbed ovulatory function 
with chronic oligomenorrhea (cycle length > 35 d; less 
than nine cycles per year) or amenorrhea (cycle length 
>12 wk) and patients with typical appearance of 
polycystic ovaries by ultrasound were included. 
Patients with thyroid problem, tubal defects or on 
previous medications and patients with azoospermic 
husbands were excluded from the study. 
     The patients in Group A were those who gave 
consent (n=170) to take Metformin for three months 
and Group B patients were those who gave consent 
(n=145) to take Metformin for six months. The 
Glucophage (Metformin hydrochloride) drug which 
belong to oral Biguanide group by Merck was started 
in low dose to avoid its side effects. Initially the 
patients were advised to take 500 mg tablet daily. They 
were given half tablet in morning and half in the 
evening for the first week and in the next week 500 mg 
tablet twice that is one in the morning and one in the 
evening. In the third week the dose was increased to 
500 mg three times daily. In Group A 16 patients 
discontinued the treatment in a period of one month 
this included two patients with tubal defects and in 
Group B 11 patients discontinued the treatment after a 
period of 15 days, this included one patient with tubal 
defect. In Group A total number of patients who 
continued the treatment of Metformin for three 
months was 154 and in Group B 134 patients 
continued treatment for six months. Later on they 
were given combination treatment of Metformin with 
ovulation induction medicines such as clomiphene 
citrate and human menopausal gonadotrophins and 
were regularly monitored with ultrasound for 
ovulation. The ovulation induction medicines were 
given for three cycles. When they were given 
ovulation induction medicines along with Metformin 
all the patients either reported menstruation and those 
with no menstruation at the end of month were 
investigated for pregnancy. If they missed the next 
period their urine and blood HCG was done and 
ultrasonography was done to assess any sac or 
formation of fetal pole. Routine ultrasonography was 
done for nine months in these patients to assess any 
complication of pregnancy.  
      The patients who did not conceive were given no 
further treatment.  The patients who conceived at the 
time of their conception were given the option to 
continue with low dose of Metformin 500 mg ½ tablet 
three times a day throughout their pregnancy period. 
Meanwhile their blood sugar levels were continually 
monitored and they were given vitamin supplements. 
Of the total conceived patients those who signed the 
consent to continue the treatment throughout their 
pregnancy were placed in group I. The patients who 
did not give the consent to continue Metformin 
throughout their pregnancy duration were placed in 
group II. During the study the complications of 
pregnancy, births, delivery, any postnatal death and 
single or multiple births were evaluated in each 
woman. Statistical analysis was done by using SPSS 
and Pearson Chi-Square test was used. The level of 
significance was taken as P<0.05 
 
Results 
      The total number of patients in Group A and B 
were 154 and 134 respectively. In Group A mean age 
of the patient who conceived were of younger age 
(26.5+0.137 years) than those who did not conceive 
(31.08+0.22 years).The former patients were 
significantly younger than the latter patients (t(152)= 
4.64;P<0.001). In Group B the mean age of the patients 
who conceived   (27.7+0.32 years) were highly 
significantly younger than those who did not conceive 
(32.6+0.42 years) (t(132)= 6.62;P<0.001). The results 
showed that patients younger in age responded to the 
treatment in terms of conception which was not 
observed in the case of older infertile patients. The 
overall conception in Group A (36.36%) were highly 
significantly low (p=0.0001) compared to those in 
Group B (Table 1).  Table 2 represents outcome of 
pregnancy in patients conceived   after giving initial 
Metformin therapy for three months (Group A) and 
further treatment with Metformin and Ovulation 
Induction Medicines (Clomiphene Citrate and Human 
Menopausal Gonadotrophin) in group I patients who 
continued Metformin during their pregnancy duration 
and in group II who did not continue Metformin 
during their pregnancy duration.   
    Group A and B were divided into group I and group 
II .Patients in group I continued with Metformin 
treatment throughout their pregnancy period. Patients 
in group II did not give consent to continue with 
Metformin treatment during pregnancy. In patients 
who continued Metformin during pregnancy single 
live births were more in group I of Group A and 
Group B while still births were more in group II of 
Group A (P=0.011) and B (P=0.005). In patients who 
did not continue Metformin during pregnancy 
complications like threatened abortion and abortion 
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(P=0.006) were found in Group A and (P=0.002) in 
Group B. Preterm delivery (P=0.048) was seen in 
Group A and (P=0.085) in Group B (Table 2). Table 3 
represents  outcome of pregnancy in patients 
conceived   after giving initial Metformin therapy for 
six months (Group B) and further treatment with 
Metformin and Ovulation Induction Medicines 
(Clomiphene Citrate and Human Menopausal 
Gonadotrophin) in group I patients who continued 
Metformin during their pregnancy duration and in 
group II who did not continue Metformin during their 
pregnancy duration.   
 
Table I: Conception in patients taking Metformin  
   
Group A(n=154) 
Metformin for 3 
months 
Group 
B(n=134) 
Metformin 
for 6 
months p- value 
conceived   No(%) 56(36.36) 86(64.18) 0.0001* 
Not conceived  
No(%) 98(63.6) 48(35.82) 0.0001* 
*Conceived and Not-conceived patients of Group A vs Group B ; 
p=0.0.5 
Table 2: Outcome of pregnancy in patients 
conceived   after giving Metformin therapy  
Group A (n=56) 
  Group I 
(n=31) 
Continued 
Metformin 
during 
pregnancy 
Group 
II(n=25) 
Metformin 
 not 
continued 
during 
pregnancy 
p- 
value 
 
Complications 
No 
complication 
Threatened 
abortion 
Abortion 
28 
 
3 
0 
14 
 
6 
5 
 
0.006 
 
Births 
Abortion 
Single live 
birth 
Multiple live 
birth 
Still births 
0 
 
29 
 
2 
0 
 
5 
15 
 
3 
2 
 
 
0.011 
Delivery Normal 
Preterm 
postterm 
29 
1 
1 
19 
6 
0 
 
0.048 
Post natal 
death 
Nil 
death 
31 
0 
21 
4 
 
0.021 
Single/Multiple 
births 
Single births 
Multiple 
births 
29 
2 
22 
3 
 
0.469 
n= number of patients;*p<0.05 
 
Discussion 
        Treatment with Metformin resulted in 
conceptions of comparatively     younger           women  
 
Table 3: Outcome of pregnancy in patients 
conceived   after giving initial Metformin 
therapy for six months   ;    Group (n=86) 
  Group I 
(n=34) 
Metformin 
continued 
during 
pregnancy 
Group II 
(n=52) 
Metformin 
discontinued 
during 
pregnancy 
p- 
value 
Complcations No 
Complication 
Threatened 
abortion 
Abortion 
 
34 
0 
 
0 
 
36 
6 
 
10 
 
0.002 
 
Births 
Abortion 
Single live 
birth 
Multiple live 
birth 
Still births 
0 
 
33 
1 
 
0 
10 
 
34 
3 
 
5 
 
 
0.005 
Delivery Normal 
Preterm 
postterm 
31 
1 
2 
46 
6 
0 
 
0.084 
Post natal 
death 
Nil 
death 
33 
1 
48 
4 
0.357 
Single/Mult
iple births 
Single births 
Multiple 
births 
33 
1 
49 
3 
0.543 
n= number of patients;*p<0.05 
(27.09+1.0 years) than older women (29.04+0.66 
years).Younger patients after six months treatment 
with Metformin conceived even without taking 
ovulation induction medicines. Similar findings were 
seen in other studies  which revealed that predictive 
power of age was highest whereas no effect of age was 
seen on ovulation or the treatment cycles, 13,14In our 
study those patients who were given 6 months 
treatment with Metformin responded significantly in 
terms of conception than those who took Metformin 
treatment only for three months. This suggests that 
initial duration of treatment is highly effective for 
conception. Clomiphene citrate and Human 
Menopausal Gonadotrophins in combination with 
Metformin has proved a better medicine for the 
treatment of infertility in PCOS.  
     In another study it was concluded that clomiphene 
(dosage 150 mg/day for 5 days) resulted in 
significantly greater live birth rates than metformin. 
This study concluded that clomiphene is superior to 
metformin as first-line therapy for infertility in women 
with PCOS15. In other study it was concluded that 
metformin is superior to clomiphene to achieve a 
singleton gestation for all pregnancies but with 
clomiphene (50 mg/day) they observed multiple 
pregnancies with significant neonatal and maternal 
morbidity, and neonatal mortality.16 The other  
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researchers concluded that non-obese women with 
PCOS and infertility treated  with Metformin had  
greater live birth rate than those treated with 
clomiphene (58 vs. 19%) and 6-month clomiphene or 
metformin treatment resulted in cumulative 
pregnancy rates of 49 and 63%, respectively (P= 0.2).17 
In the present study the group of patients who were 
given Metformin for six months and those who 
conceived live birth rate and single births were 
significantly higher in patients who continued 
Metformin during pregnancy duration. Abortions, still 
births and threatened abortions were higher in 
patients who did not continue Metformin during the 
pregnancy.Different authors using metformin reported 
less pregnancy complications.18 The findings support 
the hypothesis that decreasing hyperinsulinemic 
insulin resistance, with metformin, in women with the 
polycystic ovary syndrome, decreases the rate of early 
pregnancy loss. In contrast, the rate of early pregnancy 
loss of 8.8% in the women treated with metformin is 
similar to the rate of 10–15% reported for clinically 
recognized pregnancies in normal women.19,20 84 
fetuses of the women treated with metformin there 
were 63(75%) normal live births and 14 (17%) first 
trimester spontaneous abortions. 100 fetuses of women 
who did not take metformin had 34(34%) live births 
and 62(62%) spontaneous abortions. Like the present 
study they concluded that metformin therapy during 
pregnancy in women with PCOS was associated with 
reduction in spontaneous abortions  and early 
pregnancy loss in women with PCOS.21,22 There have 
been no demonstrable teratogenic effects, intrauterine 
deaths and stillbirths reported with Metformin use in 
pregnancy.23  
 
Conclusion 
 1.Metformin results in conceptions of comparatively 
younger women than older women.  
2. Overall conceptions after six months treatment with 
Metformin are  significantly more compared to those 
who were given Metformin for three months.  
3.Metformin taken during the pregnancy improves the 
outcome of pregnancy. 
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